Document:

exv10w71

			
	 	 	 
	 
	 	Exhibit 10.71

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE
24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

April 16, 2009

GlaxoSmithKline

709 Swedeland Road

UW2328

King of Prussia, Pennsylvania 19406

			
	Attn:	 	Adrian Rawcliffe

Senior Vice President, Worldwide Business Development and R&D Finance

Re: Expiration of the GSK Option

Dear Mr. Rawcliffe:

As you know, Glaxo Group Limited (“GSK”) and Cytokinetics, Inc. (“CK”) are parties
to that certain Collaboration and License Agreement dated June 20, 2001, as amended (the
“Agreement”). This letter (this “2009 Amendment”) sets forth the Parties’
agreement with respect to certain matters relating to the expiration of the GSK Option granted to
GSK pursuant to the Amendment to the Agreement dated November 27, 2006 (the “November 2006
Amendment”).

Now therefore, GSK and CK agree, effective as of 5 p.m., P.S.T., April 17, 2009 (the “2009
Amendment Effective Date”), as follows:

	1.	 	Definitions. All capitalized terms not defined herein shall have the meaning
ascribed to them in the Agreement.
	 
	2.	 	Royalties Due to GSK.

	 	(a)	 	Royalty Rates. As determined by the Parties in accordance with Section
4.7 of the Agreement and Section 20 of the November 2006 Amendment, CK shall pay to GSK
a royalty of [***] percent (***%) of total annual worldwide Net Sales of any CK
Product, subject to the terms below. If CENP-E should become a CK Target following the
2009 Amendment Effective Date, then Section 4.7 of the Agreement shall continue to
apply with respect to any CK Products directed to the inhibition of CENP-E.
	 
	 	(b)	 	Royalty Determination. For purposes of determining the royalties due
on CK Products, Sections 1.50, 6.6.3(a) and 6.7 through 6.15, inclusive, of the
Agreement shall apply, subject to the following modifications:

	 	(i)	 	With regard to Section 1.50 of the Agreement, (a) all
references to GSK shall be deemed to refer to CK, and vice-versa, (b) all
references to Licensed Product(s) shall be deemed to refer to CK Products, and
(c) all references to Development

			
	 	 	 
	2009 Amendment Execution Version
	 	Page 1 of 11

***  Certain information on the page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

	 	 	 	Compound(s) shall be deemed to refer to CK Compound(s). In addition, the
third paragraph of Section 1.50 shall read as follows:

	 	 	 	“In the event a CK Product is sold which is a Combination Product
under Section 1.14, for purposes of determining payments due to GSK,
Net Sales of such Combination Products shall be calculated by
multiplying the Net Sales of the Combination Product by the fraction
A over A+B, in which A is the Gross Selling Price of the CK Product
when such Product is sold in substantial quantities comprising a CK
Compound as the sole therapeutically active ingredient during the
applicable accounting period in which the sales of the CK Product
were made, and B is the Gross Selling Price of the other
therapeutically active ingredients or [***] (as defined below)
contained in the Combination Product sold separately in substantial
quantities during the accounting period in question. All Gross
Selling Prices of the therapeutically active ingredients and [***] in
the Combination Products that are CK Products shall be calculated as
the average Gross Selling Price of such therapeutically active
ingredients and [***] during the applicable accounting period for
which the Net Sales are being calculated. In the event that no
separate sale of either the CK Product comprising a single CK
Compound as the sole therapeutically active ingredient or the other
therapeutically active ingredients or [***] in the Combination
Product are made during the accounting period in which the sale was
made or if the Gross Selling Price for a particular therapeutically
active ingredient or [***] cannot be determined for an accounting
period, Net Sales allocable to the CK Product portion of the
Combination Product shall be determined by mutual agreement reached
in good faith by the Parties prior to the end of the accounting
period in question based on an equitable method of determining same
that takes into account, in the Territory, variations in potency, the
relative contribution of each therapeutically active ingredient or
[***] in the Combination Product, and relative value to the end user
of each therapeutically active ingredient or [***]. For purposes of
this Section 1.50, (i) [***] shall mean [***], including a [***],
that forms part of a [***], and (ii) “Gross Selling Price” shall mean
the gross price at which an active ingredient or [***] is sold to a
Third Party, before discounts, deductions, credits, taxes or
allowances.”

	 	(ii)	 	With regard to Section 6.6.3(a), all references to “Licensed
Product” shall be deemed to refer to CK Product(s).
	 
	 	(iii)	 	With regard to Section 6.7 of the Agreement, (a) all
references to Compound shall be deemed to refer to CK Compound, (b) all
references to Licensed Product(s) shall be deemed to refer to CK Product(s),
and (c) the phrase “under Section 6.6” shall be replaced with “payable to GSK
with respect to CK Products”.
	 
	 	(iv)	 	With regard to Section 6.8 of the Agreement, all references to
CK shall be deemed to refer to GSK.

			
	 	 	 
	2009 Amendment Execution Version
	 	Page 2 of 11

***  Certain information on the page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

	 	(v)	 	With regard to Section 6.9 of the Agreement, all references to
GSK shall be deemed to refer to CK, and vice-versa.
	 
	 	(vi)	 	With regard to Section 6.12 of the Agreement, the following
terms shall apply:
	 
	 	 	 	(a) 6.12.1 Right of [***]. In the event that (i) it becomes
necessary for [***] to [***] under [***] of a Third Party, where such [***]
or [***] of a CK Compound comprising a CK Product, or the [***] or [***] (as
defined below) of the CK Target to which such CK Product is directed, which
CK Compound or CK Target is within the GSK Existing Technology or consists
of Collaboration or Post-Collaboration Technology owned solely or jointly by
GSK, and such [***] would [***] or [***] of such CK Product (but not, for
example, by reason of its [***] or [***]), and (ii) [***] must [***] such
Third Party for such [***] on [***] of such CK Product [***], [***] may
[***] that [***] of the [***] to such Third Party as the Parties agree under
Section [***] of this 2009 Amendment (i.e., paragraph [***]), but in no
event more than [***] percent ([***]%) of such [***], against [***] on [***]
of such CK Product, as specified in paragraph [***] of this 2009 Amendment,
subject in each case to the [***] of [***] specified in Section [***].
[***] shall not be entitled to such [***] in [***] in the event the [***] of
such Third Party for which such [***] have been incurred are [***] or [***].
For purposes of this Section 6.12.1, a [***] shall “[***] of the CK Target”
if such [***] a [***] or [***] by [***] of such CK Target.
	 
	 	 	 	(b) 6.12.2 Consultation: Disputes. [***] shall consult with
[***] prior to [***] entering into any [***] with a Third Party for which
[***] would seek to [***] under this subsection 6.12, and shall take into
account reasonable suggestions of [***] with respect to such proposed [***].
Any dispute under this subsection (b), including any dispute as to whether
such a [***] is necessary, shall be subject to and resolved in accordance
with Section 12.3.1 of the Agreement
	 
	 	 	 	(c) 6.12.3 [***]. In addition to the [***], it is understood that
on a case-by-case basis, CK and GSK may agree that it would be in their
mutual best interests for [***] to [***] a [***] for [***] with a CK
Product, and in such case may similarly agree that it would be in their
mutual best interests to [***] with respect to such [***]; provided,
however, that neither Party shall be obligated to agree to any such [***],
and no such [***] unless so agreed.
	 
	 	(vii)	 	With regard to Section 6.13 of the Agreement, the following
terms shall apply:
	 
	 	 	 	6.13 [***] in [***] for [***]. If [***] occurs in [***] or [***]
of the [***] between a CK Product being marketed and sold under this
Agreement by CK, its Affiliates or Sublicensee(s) and any [***] (as defined
below) [***] and [***]

			
	 	 	 
	2009 Amendment Execution Version
	 	Page 3 of 11

***  Certain information on the page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

	 	 	 	(other than a CK Affiliate or Sublicensee), and for so long as such [***] is
[***] and [***] in such [***] or [***] of [***], and [***] of such [***]
percent ([***]%) of the total [***] of such [***] and the CK Product in the
[***] in such Contract Year, the [***] under this 2009 Amendment in respect
of such [***] or [***] shall be [***] to the extent provided in Section
[***] (i.e., paragraph [***] below). CK shall give GSK [***] of such [***]
with suitable and reasonable supporting documentation. Any [***] in the
[***] as a result of such [***] shall apply from the [***] by CK to GSK of
such [***] and shall be [***] only for the period such [***], subject in
each case to Section [***] below. For the purposes of this Section 6.13, a
“[***]” shall mean any [***] (other than a CK Product sold by or
under authority of CK) containing the [***] as the [***] in the CK Product
being sold by CK or its Affiliate or Sublicensee in such [***], and which
[***] the CK Product in the [***] or [***].
	 
	 	(viii)	 	With regard to Section 6.14 of the Agreement, the following terms shall
apply:
	 
	 	 	 	(a) 6.14.1 Conditions to [***]. It is understood that, if [***] of
a CK Product [***] are [***] by the [***] or by [***], [***] will be [***]
by [***] due to [***]. Consequently, the Parties acknowledge that Sections
6.12 and 6.13 above are intended only to avoid a [***] on [***] in the event
described herein. Accordingly, notwithstanding Section 6.12 or 6.13, the
[***] with respect to [***] of a CK Product [***] shall only be [***] if
[***] and [***] of such CK Product in [***] have been [***] by reason of
either [***] or [***], and the [***] under this 2009 Amendment would create
[***] between CK and GSK with respect to the [***] of such CK Product in
[***] without a [***] under Section 6.12 or 6.13, as applicable. In
addition:

	 	(i)	 	Before any [***] under Sections
6.12 or 6.13 above shall take effect, CK shall consult with GSK
as to measures that can reasonably be taken to [***] of such
[***] or [***] in such [***]; and
	 
	 	(ii)	 	[***] under Sections 6.12 or 6.13
above shall continue only if CK reasonably initiates and
continues to progress such [***]; and
	 
	 	(iii)	 	Any [***] under Sections 6.12 or
6.13 above shall continue only if CK continues to pursue all
reasonably available legal measures that could [***] or [***]
the [***]or [***] or [***], as applicable, including the [***]
of any [***] that could [***] or

			
	 	 	 
	2009 Amendment Execution Version
	 	Page 4 of 11

***  Certain information on the page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

	 	 	 	[***] of a [***], directly or indirectly, and the [***] of any
applicable [***] or [***] that could affect the [***].

	 	 	 	(b) 6.14.2 Amount of [***]. The amount of the [***] under Sections
6.12 and 6.13 above shall be reasonably agreed by CK and GSK, taking into
account the factors described in this Section 6.14, provided that the [***]
otherwise [***] on such [***] shall not be so [***], after [***] or [***]
under this Agreement, if any, to [***], as specified in paragraph [***] of
this 2009 Amendment.
	 
	 	 	 	(c) 6.14.3 In the event the Parties are unable to agree on such [***], the
amount of the [***] shall be subject to and resolved in accordance with
Section 12.3.1 of the Agreement. In any event, however, the [***] shall
only apply for so long as the circumstances and conditions described in
Sections 6.12 or 6.13 above continue to exist, and shall only apply to [***]
on [***] of the particular CK Product [***].

	 	 	 	(ix) With regard to Section 6.15 of the Agreement, all references to GSK shall be
deemed to refer to CK, and vice-versa, and the reference to Licensed Product will be
deemed to refer to CK Product.

	3.	 	Section 1.14 shall be revised to read in its entirety as follows:
	 
	1.14	 	“Combination Product” shall mean (a) a Licensed Product that is a
pharmaceutical preparation for human use incorporating two or more therapeutically active
ingredients, including a Development Compound, as its main active ingredients, or (b) a CK
Product that is a pharmaceutical preparation for human use incorporating two or more
therapeutically active ingredients, including a CK Compound, as its main active ingredients.
Notwithstanding the foregoing, drug delivery vehicles, adjuvants, and excipients shall not
be deemed to be “therapeutically active ingredients,” and their presence shall not be deemed
to create a Combination Product; provided that a [***], as defined in the November 2006
Amendment, containing one or more Licensed Product(s) or one or more CK Product(s) shall be
deemed to be a Combination Product.
	 
	4.	 	Section 6.10 of the Agreement shall be revised to read in its entirety as follows:
	 
	6.10	 	Timing of Royalty Payments and Reports. Royalty payments under this Agreement
shall be made to GSK or its designee, or CK or its designee, as the case may be, quarterly
within ninety (90) days following the end of each calendar quarter for which royalties are
due. Each royalty payment shall be accompanied by a report summarizing the applicable Net
Sales during the relevant three (3) month period.
	 
	5.	 	KSP Exclusivity. Section 24(c) of the November 2006 Amendment is hereby amended so
that all text following “...for purposes of the [***] above” is deleted. As amended, Section
24(c) of the November 2006 Amendment shall continue in full force and effect until [***],
subject to the limitations set forth in Section 24(c) of the November 2006 Amendment.

			
	 	 	 
	2009 Amendment Execution Version
	 	Page 5 of 11

***  Certain information on the page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

	6.	 	[***]. Section [***] of the Agreement is hereby deleted in its entirety.
	 
	7.	 	University License. The second sentence of Section 8.4.1 of the Agreement is hereby
revised to read as follows: “As and to the extent required for the furtherance of the
objectives of this Agreement, CK shall use [***] to maintain the University License and to
timely pay all fees due under the University License.” The other sentences in Section 8.4.1
remain in full force and effect.
	 
	8.	 	Confidential Information. The Parties agree that CK’s rights under Sections 9.2 and
9.5 of the Agreement with respect to Confidential Information and Licensed Technology relating
to CK Targets, CK Compounds and/or CK Products shall include the right of CK to use and
disclose any such Confidential Information and Licensed Technology in connection with the
performance of its obligations and/or exercise of any rights expressly granted or reserved to
CK in the Agreement (including without limitation, in this 2009 Amendment and/or the November
2006 Amendment). In addition, notwithstanding Section 12.1, CK may disclose the financial
terms of the Agreement, including without limitation this 2009 Amendment, relating to CK
Targets, CK Compounds and CK Products to potential partners, sublicensees or assignees, under
confidentiality provisions comparable to those in the Agreement. Upon the reasonable request
of GSK, CK shall identify the potential partners, sublicensees or assignees to which CK has
disclosed the financial terms of the Agreement relating to CK Targets, CK Compounds and CK
Products; provided that CK shall not be required to identify to GSK any such potential
partner, sublicensee or assignee if CK is contractually prohibited from doing so. CK shall
have no further obligation to provide to GSK for pre-disclosure review, comment or approval,
any proposed public disclosure relating to any CK Target, CK Compound and/or CK Product. GSK
shall not disclose to any Third Party any Confidential Information relating to any CK Target,
CK Compound or CK Product, without CK’s further express written consent.
	 
	9.	 	Assignment of Rights and Obligations. Notwithstanding Section 12.5.1 of the
Agreement, CK may assign any and/or all of its rights and obligations under the Agreement
relating to any CK Target or CK Compound without GSK’s written consent, provided that such
entity agrees in writing to be bound by the applicable terms and conditions of the Agreement.
CK shall promptly notify GSK in writing of any such assignment and shall provide GSK with a
copy of any applicable assignment or other agreement.
	 
	10.	 	Close-Out Activities. GSK shall perform the activities and provide the deliverables
set forth in Exhibit A in accordance with the timelines set forth therein. The Parties will
act promptly to address and finalize all items listed on Exhibit A.
	 
	11.	 	Further Actions. Each Party agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary and/or appropriate in order to
carry out the purposes and intent of this 2009 Amendment.
	 
	12.	 	No Effect on CENP-E as a Target. The Parties acknowledge that this 2009 Amendment
has no effect on the provisions of the Agreement applicable to CENP-E as a Collaboration
Target and GSK’s development of Licensed Products targeting CENP-E. All terms and conditions
of the Agreement as they apply to CENP-E, GSK’s development activities directed to CENP-E, and
GSK’s commercialization of any Licensed Product targeting CENP-E remain in full force and
effect.

			
	 	 	 
	2009 Amendment Execution Version
	 	Page 6 of 11

***  Certain information on the page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

	13.	 	Publications. The provisions in Section 9.4 of the Agreement, as amended by the
November 2006 Amendment, shall no longer apply to any publications by CK regarding any CK
Product, except to the extent that such publication contains Confidential Information of GSK.
Notwithstanding Section 8(d) of the November 2006 Amendment, CK shall have the right, but not
the obligation, to complete and publish the manuscripts for the GSK-Sponsored Studies where CK
considers such publication appropriate, provided that CK shall include GSK authors when GSK
generated data are used in the publication, as appropriate, on such publications and, when
such GSK authors are included, GSK shall have the opportunity to review and comment on any
such publication prior to its publication.
	 
	14.	 	Miscellaneous. Except as specifically modified or amended hereby, the Agreement
shall remain in full force and effect and, as modified or amended, is hereby ratified,
confirmed and approved. No provision of this 2009 Amendment may be modified or amended except
expressly in a writing signed by both Parties, nor shall any terms be waived except expressly
in a writing signed by the Party charged therewith. This 2009 Amendment shall be governed in
accordance with the laws of the State of New York, without regard to principles of conflicts
of laws.

[The remainder of this page intentionally left blank; signature page follows.]

			
	 	 	 
	2009 Amendment Execution Version
	 	Page 7 of 11

 

 

If the foregoing is acceptable, please have an authorized representative of GSK countersign this
2009 Amendment where indicated below. Please return one fully executed original to my attention.

Sincerely,

/s/ Michael S. Rabson, Ph.D.

Michael S. Rabson, Ph.D.

Sr. Vice President, Business Development & Legal Affairs,

and General Counsel

Cytokinetics, Inc.

Agreed and accepted:

GLAXO GROUP LIMITED

By: /s/ Paul Williamson

Name: Paul Williamson

Title: For and on behalf of

Edinburgh Pharmaceutical Industries Limited

Corporate Director

Date:                                                             

			
	cc:	 	Vinod Ramachandran, Ph.D.,

Alliance Director, GlaxoSmithKline

Lisa A. DeMarco, Esq.,

VP & Associate General Counsel, GlaxoSmithKline, Legal Operations

			
	 	 	 
	2009 Amendment
	 	Signature Page

 

 

EXHIBIT A

ACTIVITIES/DELIVERABLES

[***]

			
	 	 	 
	2009 Amendment Execution Version
	 	Page 9 of 11

***  Certain information on the page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

[***]

Rest of page intentionally left blank

[***]

			
	 	 	 
	2009 Amendment Execution Version
	 	Page 10 of 11

***  Certain information on the page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

[***]

			
	 	 	 
	2009 Amendment Execution Version
	 	Page 11 of 11

***  Certain information on the page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.exv10w73

EXHIBIT 10.73

AMENDMENT NO. 1

     THIS AMENDMENT NO. 1 is made and effective as of the 1st day of January 2005, between General
Electric Capital Corporation (“Secured Party”) and Cytokinetics, Incorporated. (“Debtor”) in
connection with that certain Master Security Agreement, dated as of February 2, 2001 (“Agreement”).
The terms of this Amendment No. 1 are hereby incorporated into the Agreement as though fully set
forth therein. Secured Party and Debtor mutually desire to amend the Agreement as set forth below.
Section references below refer to the section numbers of the Agreement.

     Sections 7(a)(xii) and (xiii) are hereby added and read as follows:

     “(xii) Debtor has committed a Material Default under a Material Agreement. As used in the
foregoing sentence:

          (1) “Material Default” means a default: (a) as defined by the terms of the applicable
agreement; (b) for which Debtor has received written notice from the other party to such agreement
to the extent required by and in accordance with the terms of such agreement; and (c) that Debtor
has not cured within the time period for cure set forth in such agreement; and

          (2) “Material Agreement” means an agreement between Debtor and a third party where: (a) the
Debtor is obligated make payments in respect of (i) borrowed money, provided that the primary
purpose of such agreement is to borrow money, (ii) the deferred purchase price of real property or
(iii) any lease agreement for real property; and (b) such agreement is required to be filed
with the United States Securities and Exchange Commission;

     (xiii) Secured Party shall have determined in its good faith, reasonable judgment that there
has been a Material Adverse Change. As used in the foregoing sentence, “Material Adverse Change”
means a material adverse change in Debtor’s financial condition that would prevent the fundamental
and basic operation of Debtor’s primary business and materially impair the ability of Debtor to
perform its obligations hereunder or of Secured Party to enforce the Indebtedness or realize upon
the Collateral; provided, however, that a Material Adverse Change shall not be
deemed to have occurred solely because of one or more of the following:

     (a) any failure of Debtor to meet estimates of revenue or earnings;

     (b) a change in the market price or trading volume of Debtor’s Common Stock; or

     (c) any adverse change or event that affects, as a whole, the industry in which Debtor
competes;

Page 1 of 2

 

     provided, further, however, that the occurrence of any of the
three foregoing events may, in combination with other adverse changes specific to Debtor’s
financial condition, form the basis, in the aggregate, on which Secured Party determines
that a Material Adverse Change has occurred.

     Section 7(e) of this Agreement shall not apply to any dispute or action solely to the extent
relating to any default or alleged default under Section 7(a)(xii) and/or Section 7(a)(xiii) of
this Agreement. With respect to any dispute or action relating to any default or alleged default
under Section 7(a)(xii) and/or Section 7(a)(xiii), the prevailing party in such proceeding, as
determined by a court of competent jurisdiction, will be entitled to receive its reasonable
attorneys’ fees, expert witness fees and out-of-pocket costs incurred in connection with such
proceeding, in addition to any other relief it may be awarded.”

TERMS USED, BUT NOT OTHERWISE DEFINED HEREIN SHALL HAVE THE MEANINGS GIVEN TO THEM IN THE
AGREEMENT. EXCEPT AS EXPRESSLY AMENDED HEREBY, THE AGREEMENT SHALL REMAIN IN FULL FORCE AND EFFECT.
IF THERE IS ANY CONFLICT BETWEEN THE PROVISIONS OF THE AGREEMENT AND THIS AMENDMENT NO. 1, THEN
THIS AMENDMENT NO. 1 SHALL CONTROL.

     IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 1 by signature of
their respective authorized representative set forth below.

	 	 	 	 	 	 	 	 	 	 	 
	General Electric Capital Corporation	 	 	 	Cytokinetics, Incorporated	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Diane Earle
 

	 	 	 	By:
	 	/s/ Robert I. Blum
 

	 	 
	Name:

	 	Diane Earle
	 	 	 	Name:
	 	Robert I. Blum	 	 
	Title:

	 	Senior Vice President
	 	 	 	Title:
	 	EVP, Corp. Dev. & Com. Ops., & CBO	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Date:

	 	3/24/05
	 	 	 	Date:
	 	March 23, 2005	 	 

Page 2 of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}]]